This review summarizes the pharmacokinetic, pharmacodynamic, efficacy, and safety profiles of apixaban and edoxaban for stroke prevention in nonvalvular atrial fibrillation based on Phase III trials and indirect comparisons.
Answers are grounded in this paper and cite their sources.
May guide NOAC selection in nonvalvular AF; leaves open need for head-to-head RCTs.
Oral anticoagulation therapy is the mainstay of stroke prevention in nonvalvular atrial fibrillation patients. Vitamin K antagonists (such as warfarin) have been effective conventional oral anticoagulants for several decades. However, due to their limitations in clinical use, several nonvitamin K antagonist oral anticoagulants (NOACs, including dabigatran, rivaroxaban, apixaban and edoxaban) have been developed. Nonetheless, no head to head trials have been performed to directly compare these NOACs in patient cohorts. In this review article, two direct factor Xa inhibitors, apixaban and edoxaban, are briefly described with focus on their pharmacokinetic and pharmacodynamic profiles, plus drug interactions. Moreover, both efficacy and safety will be discussed based on the available data from the large Phase III clinical trials and indirect comparison studies.
No takes yet. Share an insight, caveat, or question.
Xiong et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: